Medical devices, healthcare technology and the business of care
510(k) clearance · K260331

IMMULITE 2000 3gAllergy Specific IgE Vantage; IMMULITE 2000 Systems Peanut Allergen (F13)

Siemens Healthcare Diagnostics Products, Ltd. · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONK260331

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 4, 2026 for K260331, a traditional 510(k) submitted February 2, 2026 by Siemens Healthcare Diagnostics Products, Ltd. The device is the IMMULITE 2000 3gAllergy Specific IgE Vantage with IMMULITE 2000 Systems Peanut Allergen (F13), a quantitative chemiluminescent immunoassay for allergen-specific IgE to whole peanut extract in human serum, run on the IMMULITE 2000 XPi System under product code DHB, Class II, 21 CFR 866.5750. Clearance is not a PMA approval.

The comparison document names K013134, the IMMULITE 2000 Allergen Specific IgE Kit, as predicate, with chemiluminescence, serum sample type, 65-minute process time, detection antibody and bead chemistry listed as the same. Recorded differences are the F13 whole peanut extract allergen, an added recombinant sheep monoclonal high-biotin-affinity accessory reagent, and a 30 µL versus 50 µL sample volume. A separate CLIA listing shows the assay as moderate complexity effective September 11, 2026. The provided materials give no analytical performance results, so accuracy and clinical performance remain unknown here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Immunology
Decision date
Sep 4, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260331
Regulatory pathway
510(k) premarket notification
Product code
DHB
Decision code
SESE
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Test, Radioallergosorbent (Rast) Immunological.

Product code
DHB
FDA device class
2

FDA decision timeline

  1. K260331 received

    Application receipt date recorded by FDA.

  2. K260331 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DHB

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics Products, Ltd.510(k) clearanceNov 2, 2026FDA
Hycor Biomedical510(k) clearanceJul 24, 2026FDA
Hycor Biomedical510(k) clearanceJul 21, 2026FDA
Hycor Biomedical510(k) clearanceJun 18, 2026FDA
Hycor Biomedical510(k) clearanceMay 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics Products, Ltd.

Headquarters
Not reported
FDA applicant address
Llanberis

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records